Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524064 · ClinicalTrials.gov registry record · NA
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax
A NA study of Bone Metastases in the Thorax, sponsored by Varian, a Siemens Healthineers Company.
- Active
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT05524064 is a NA study of Bone Metastases in the Thorax that is active but no longer recruiting, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 10 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05524064, a NA study of Bone Metastases in the Thorax, is active but no longer recruiting, sponsored by Varian, a Siemens Healthineers Company.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess toxicities of FLASH radiotherapy treatment and pain relief in subjects with painful thoracic bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
Conditions Studied
Interventions
- RADIATION FLASH Radiotherapy
Study Locations (2)
Illinois
- OSF Healthcare Saint Francis Medical Center - Peoria
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05524064
The ClinicalTrials.gov registry entry for NCT05524064 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Varian, a Siemens Healthineers Company, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Metastases in the Thorax appearing as the primary indexed condition, and to 1 intervention - of which FLASH Radiotherapy is the first listed.
NCT05524064 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Ohio.
Frequently Asked Questions
What is clinical trial NCT05524064 about?
NCT05524064 is a clinical study titled "FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax". The purpose of this study is to assess toxicities of FLASH radiotherapy treatment and pain relief in subjects with painful thoracic bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
What is the current status of trial NCT05524064?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2023-03-08. Estimated completion is 2027-05-01.
What conditions does trial NCT05524064 study?
This clinical trial studies the following conditions: Bone Metastases in the Thorax.
What interventions are being tested in trial NCT05524064?
The interventions under investigation include: FLASH Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT05524064?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05524064 being conducted?
This trial has 2 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.